Author Question: When you provide a reinforcer after each response in backward and forward chaining the outcome of ... (Read 218 times)

Chloeellawright

  • Hero Member
  • *****
  • Posts: 588
When you provide a reinforcer after each response in backward and forward chaining the outcome of that response becomes a:
 
  a. conditioned stimulus for the next response
  b. S-delta for the next response
 c. conditioned reinforcer
 d. A and C

Question 2

Which of the following is used in a behavioral contract to determine whether the target behavior occurred or did not occur?
 
  a. verbal reports of the client
 b. permanent products of the behavior
  c. self-monitoring by the client
 d. all of these



ambernicolefink

  • Sr. Member
  • ****
  • Posts: 359
Answer to Question 1

c

Answer to Question 2

b



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

In 1835 it was discovered that a disease of silkworms known as muscardine could be transferred from one silkworm to another, and was caused by a fungus.

Did you know?

The most dangerous mercury compound, dimethyl mercury, is so toxic that even a few microliters spilled on the skin can cause death. Mercury has been shown to accumulate in higher amounts in the following types of fish than other types: swordfish, shark, mackerel, tilefish, crab, and tuna.

Did you know?

All adults should have their cholesterol levels checked once every 5 years. During 2009–2010, 69.4% of Americans age 20 and older reported having their cholesterol checked within the last five years.

Did you know?

A strange skin disease referred to as Morgellons has occurred in the southern United States and in California. Symptoms include slowly healing sores, joint pain, persistent fatigue, and a sensation of things crawling through the skin. Another symptom is strange-looking, threadlike extrusions coming out of the skin.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library